Hematologic malignancies following immune checkpoint inhibition for solid tumors

Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who develop...

Descripción completa

Detalles Bibliográficos
Autores principales: van Eijs, Mick J. M., van der Wagen, Lotte E., Mous, Rogier, Leguit, Roos J., van de Corput, Lisette, van Lindert, Anne S. R., Suelmann, Britt B. M., Kamphuis, Anna M., Nierkens, Stefan, Suijkerbuijk, Karijn P. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188911/
https://www.ncbi.nlm.nih.gov/pubmed/35691988
http://dx.doi.org/10.1007/s00262-022-03230-4
_version_ 1784725477534990336
author van Eijs, Mick J. M.
van der Wagen, Lotte E.
Mous, Rogier
Leguit, Roos J.
van de Corput, Lisette
van Lindert, Anne S. R.
Suelmann, Britt B. M.
Kamphuis, Anna M.
Nierkens, Stefan
Suijkerbuijk, Karijn P. M.
author_facet van Eijs, Mick J. M.
van der Wagen, Lotte E.
Mous, Rogier
Leguit, Roos J.
van de Corput, Lisette
van Lindert, Anne S. R.
Suelmann, Britt B. M.
Kamphuis, Anna M.
Nierkens, Stefan
Suijkerbuijk, Karijn P. M.
author_sort van Eijs, Mick J. M.
collection PubMed
description Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.
format Online
Article
Text
id pubmed-9188911
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-91889112022-06-17 Hematologic malignancies following immune checkpoint inhibition for solid tumors van Eijs, Mick J. M. van der Wagen, Lotte E. Mous, Rogier Leguit, Roos J. van de Corput, Lisette van Lindert, Anne S. R. Suelmann, Britt B. M. Kamphuis, Anna M. Nierkens, Stefan Suijkerbuijk, Karijn P. M. Cancer Immunol Immunother Research Report Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms. Springer Berlin Heidelberg 2022-06-13 2023 /pmc/articles/PMC9188911/ /pubmed/35691988 http://dx.doi.org/10.1007/s00262-022-03230-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Report
van Eijs, Mick J. M.
van der Wagen, Lotte E.
Mous, Rogier
Leguit, Roos J.
van de Corput, Lisette
van Lindert, Anne S. R.
Suelmann, Britt B. M.
Kamphuis, Anna M.
Nierkens, Stefan
Suijkerbuijk, Karijn P. M.
Hematologic malignancies following immune checkpoint inhibition for solid tumors
title Hematologic malignancies following immune checkpoint inhibition for solid tumors
title_full Hematologic malignancies following immune checkpoint inhibition for solid tumors
title_fullStr Hematologic malignancies following immune checkpoint inhibition for solid tumors
title_full_unstemmed Hematologic malignancies following immune checkpoint inhibition for solid tumors
title_short Hematologic malignancies following immune checkpoint inhibition for solid tumors
title_sort hematologic malignancies following immune checkpoint inhibition for solid tumors
topic Research Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9188911/
https://www.ncbi.nlm.nih.gov/pubmed/35691988
http://dx.doi.org/10.1007/s00262-022-03230-4
work_keys_str_mv AT vaneijsmickjm hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT vanderwagenlottee hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT mousrogier hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT leguitroosj hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT vandecorputlisette hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT vanlindertannesr hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT suelmannbrittbm hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT kamphuisannam hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT nierkensstefan hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors
AT suijkerbuijkkarijnpm hematologicmalignanciesfollowingimmunecheckpointinhibitionforsolidtumors

Ejemplares similares